Sun, Aug 18 9:04am

Big Percentage Gainers (1)

Exelixis Inc [EXEL]
$21.72 1.78 (8.93%)

EXEL Profile

Sector Health Care
Industry Biotech & Pharma
Market Cap 6.31 Billion
EXEL Description

Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule cabozantinib is indicated for the treatment of patients with metastatic medullary thyroid cancer (as Cometriq) and advanced renal cell carcinoma, or kidney cancer, and hepatocellular carcinoma, or liver cancer (as Cabometyx). Exelixis and partner Roche have also brought Cotellic to market for the treatment of melanoma.


Visit Website

EXEL Earnings

EPS 0.26 P/E Ratio 15.47
Previous Earnings Wed, May 1, 2019
Latest Earnings Wed, Jul 31, 2019 (18 days ago) +2.45%

EXEL Dividend

Yield --
Ex-Date --
Pay Date --
History --

EXEL Charts

$13.42
1 Year
$25.19
Oct 29, 2018
Mar 14, 2019



Symbol Price Day % YTD %
EXEL $21.72 8.93% 8.98%

Symbol Surfing

How can we make Symbol Surfing better?

info@symbolsurfing.com

Information is provided "as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.



©2019 Symbol Surfing All Rights Reserved.

Cookies Policy | Terms Of Service | Privacy Policy